Related Experiment Videos
Arsenic trioxide, a therapeutic agent for APL
T D Zhang1, G Q Chen, Z G Wang
1The First Hospital affiliated to Harbin Medical University, 23 You Zheng Road, Nangang District, Harbin, 150001, PR China.
Oncogene
|November 13, 2001
Summary
Arsenic trioxide (As(2)O(3)) effectively treats acute promyelocytic leukemia (APL) by inducing apoptosis and differentiation. It degrades the PML-RARalpha oncoprotein, offering a targeted therapy approach for APL patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of cancer.
- APL serves as a model for differentiation therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)).
- As(2)O(3) has demonstrated high complete remission rates in APL patients.
Purpose of the Study:
- To review the therapeutic effects and mechanisms of As(2)O(3) in APL.
- To explore the dual dose-dependent effects of As(2)O(3) on APL cells.
- To highlight As(2)O(3) as a targeted therapy for human cancers.
Main Methods:
- Literature review of As(2)O(3) efficacy and side effects in APL.
- Analysis of cell biology studies on As(2)O(3) effects.
- Investigation of As(2)O(3) impact on PML-RARalpha oncoprotein expression.
Main Results:
- As(2)O(3) achieves 85-90% complete remission rates in APL patients.
- Side effects are generally mild to moderate, though severe hepatic lesions occurred in some primary cases.
- As(2)O(3) induces apoptosis at higher concentrations (0.5-2.0 microM) and partial differentiation at lower concentrations (0.1-0.5 microM).
- As(2)O(3) degrades the leukemogenic PML-RARalpha protein.
Conclusions:
- As(2)O(3) is a highly effective targeted therapy for APL.
- Understanding the mechanisms of As(2)O(3)-induced differentiation is crucial.
- As(2)O(3) represents a successful example of targeted cancer therapy.